Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras
- Monday, March 14, 2022, 7:03
- Finance
- Add a comment
Analysis of PK data from Phase 1 Multi-Ascending Dose (“MAD”) clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose (“SAD”) trial, commencing in Q2 2022, to compare fezagepras with sodium phenylbutyrate as a…
About the Author
adminasapcorp has written 41834 stories on this site.